The present invention relates to a method for producing Metal Organic Framework (MOF) having a framework that encapsulates a bio-molecule, the method comprising combining in a solution the bio-molecule and MOF precursors, wherein the bio-molecule promotes formation of the encapsulating framework.

The invention relates to an inhibitor, in particular an antisense oligonucleotide, directed against the enhancer RNA SINT1 for use in a method for the prevention or treatment of heart disease, particularly for cardiomyopathy. The antisense oligonucleotide is a gapmer or RNA interference (RNAi) agent. The antisense oligonucleotide is particularly suitable for the treatment of cardiomyopathy resulting from cardiac overload.

The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.

The present invention is directed to additive manufacturing compositions and methods for producing additive manufacturing composite blends with oxidized discrete carbon nanotubes with dispersion agents bonded to at least one sidewall of the oxidized discrete carbon nanotubes. Such compositions are especially useful when radiation cured, sintered or melt fused.

A method for producing Metal Organic Framework (MOF) having a framework that encapsulates a bio-molecule, the method comprising combining in a solution the bio-molecule and MOF precursors, wherein the bio-molecule promotes formation of the encapsulating framework.

The present invention further relates generally to novel systems, methods, and compositions for generating pharmaceutical compositions and formulations that include one or more fungal compounds and/or extracts.

The present invention relates to a compound of the following formula (I) for use as a physiological gas carrier, said gas being O.sub.2, N.sub.2, NO, NO.sub.2, H.sub.2, He and/or CO.sub.2, notably O.sub.2. The invention also relates to a non-therapeutic use of a compound of the general formula (I) for binding, carrying and/or releasing a gas, said gas being O.sub.2, N.sub.2, NO, NO.sub.2, H.sub.2, He and/or CO.sub.2, notably O.sub.2.

##STR00001##

Some aspects of the present disclosure provide nanoparticles comprising a non-cationic liposome with ligands conjugated to its surface and a hydrogel encapsulated in the liposome. In some embodiments, the nanoparticle is used as a delivery system to deliver an agent (e.g., a therapeutic agent or a genome-editing agents) to a cell (e.g., a diseased cell such as a cancer cell). The ligands on the surface of the cationic liposome targets the liposome to cells that express proteins targeted by the ligands on their surface. Methods of treating diseases and disorders, as well as methods of genome-editing are also provided.

Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.

Novel, nano-structured particles are formed by introducing a selected solid of interest into a structured fluid matrix formed by a dispersion of a small molecule host vessel components, such as a native or modified polysaccharide, cavitand, simple sugar, disaccharide, simple polyol or other similarly structured molecule known to be useful as a host vessel, in an acidic medium or other solvent, whereby the particle size of the introduced solid is reduced and or limited in the structured fluid matrix, by incorporation into or attachment to, the host vessel. The simple, one-batch mixing process results in stabilized colloidal dispersions of the nanoparticles of a variety of solids of varying scope and function and useful in a wide variety of applications, including without limitation ceramic materials, such as hexagonal boron nitride.